Innate Pharma Files Routine 6-K Disclosure
Ticker: IPHYF · Form: 6-K · Filed: Jun 4, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jun 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, routine-disclosure
TL;DR
Innate Pharma filed a 6-K, just a routine check-in, no big news here.
AI Summary
On June 4, 2024, Innate Pharma SA filed a Form 6-K, reporting its status as a foreign private issuer. The company, based in Marseille, France, is involved in the biological products sector. This filing does not contain specific financial figures or operational updates but serves as a routine disclosure.
Why It Matters
This filing indicates Innate Pharma is adhering to its reporting obligations as a foreign private issuer with the SEC, which is standard practice for companies with international listings.
Risk Assessment
Risk Level: low — The filing is a standard procedural document for a foreign private issuer and does not contain material non-public information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (company) — SEC File Number
- June 4, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to a stock exchange on which they are traded.
What is Innate Pharma SA's primary business?
Innate Pharma SA is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code 2836.
Where is Innate Pharma SA headquartered?
Innate Pharma SA is headquartered in Marseille, France, at 117 Avenue de Luminy.
Does this filing indicate Innate Pharma is submitting its annual report?
No, this filing is a Form 6-K, which is a report of foreign private issuer. The filing indicates that Innate Pharma files annual reports under cover of Form 20-F.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-04 06:03:42
Filing Documents
- a6k-iphx240604.htm (6-K) — 9KB
- exhibit991-240604.htm (EX-99.1) — 40KB
- 0001598599-24-000044.txt ( ) — 51KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date June 4, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive officer